EMD Millipore Launches Mobius® CellReady 200 L Single-use Stirred Tank Bioreactor

EMD Millipore Launches Mobius® CellReady 200 L Single-use Stirred Tank Bioreactor
Unique container design enables simple, reliable and robust installation
Mobius® SensorReady technology provides unmatched flexibility to monitor and control processes with conventional and single-use sensor technologies using a standardized process container
Open architecture allows flexibility in the choice of automation platforms
November 17, 2011, Billerica, MA - EMD Millipore, the Life Science division of Merck KGaA* of Germany, today expanded the Mobius® CellReady Bioreactor portfolio with the launch of a 200 L single-use stirred tank bioreactor for pilot- and clinical-scale mammalian cell culture. This new single-use bioreactor further demonstrates EMD Millipore's commitment to support the industry's move towards implementing complete single-use bioprocess templates.

The Mobius® CellReady 200 L bioreactor integrates a number of innovative features that deliver ease of use, reliability and operational flexibility as compared with existing single-use systems. The new offering extends the company's full-train portfolio of single-use systems, which enable customers to bring biological drugs to market faster, at a lower cost and with less risk than traditional stainless steel systems.

The innovative Mobius® SensorReady technology offers the ultimate flexibility to configure process monitoring at the point of use, reducing the need to customize bioreactor process containers and enabling easy integration of new sensor technologies. The unique rigid base and top panel design of the bioreactor process container enables simple, reliable and robust installation - improving operator confidence in set up and routine operation. The system is available as a complete, turn-key system or as a modular system to integrate with the platform of choice.

"The biopharmaceutical industry is increasingly incorporating single-use technologies to address cost pressures and accelerate the biomanufacturing process," notes Paul Chapman, Vice President of Biopharm Process Solutions. "Through incorporation of a full-train modular system that includes upstream technologies such as the Mobius® CellReady bioreactor, maximum benefit can be realized as times are reduced, risk is minimized, and market agility increases."

Details about the Mobius® CellReady 200 L bioreactor and other our complete portfolio of single-use systems are available at www.millipore.com/mobius.

About EMD Millipore
EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.

Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 68 countries and 2010 revenues of $2.2 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.

Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany

Division Information
About Millipore
Investor Relations
Careers
Media Room
Sustainability
Millipore Giving Program
Quality Assurance & Regulatory Affairs
Licensing
Events, Tradeshows & Conferences
Media Room Find A Location
Find the Millipore office or expert closest to you.

Local Millipore Offices & Phone Numbers
 Local Application Specialists
 Contact Us
We want to hear from you. Contact a specific department below or click "Suggestions and Feedback" to send your comments.

Millipore Support
 Technical Service
 Phone: 800-645-5476
 Customer Service
 Worldwide Offices
 Suggestions & Feedback

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.